August 25, 2020

POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members

TORONTO,  Aug.  25, 2020  (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a  radiopharmaceutical company dedicated to bringing the many benefits of  precision radioligand therapy to cancer patients, is announcing the  appointment of key members to its leadership team — Jessica Jensen as  Executive Vice President of Clinical Development, Valerie Hergott as  Senior Director of Chemistry, Manufacturing and Controls and Bill Demers  as Chief Financial Officer. Jessica will lead POINT’s early and late  stage clinical programs, Valerie will be responsible for POINT’s early  and late stage clinical-stage manufacturing program and Bill will be  responsible for financial governance, risk management, and overall  financial strategy.

“I am pleased to welcome  Jessica Jensen, Valerie Hergott and Bill Demers to POINT and am  confident that they will provide strong and experienced leadership,”  said Dr. Joe McCann, CEO of POINT. “Jessica has extensive experience in  leading radiopharmaceutical clinical development, Valerie has  demonstrated successes developing robust supply-chains to bring alpha  and beta-emitting radiopharmaceuticals to the clinic and Bill has worked  in both start-up and established companies, where he has built, led and  scaled financial strategy.”

Jessica Jensen  joins from Progenics Pharmaceuticals where she was the Senior VP of  Clinical Development and led their radiopharmaceutical development  programs. Valerie Hergott joins from the Centre for Probe Development  and Commercialization where she was Director of Radiopharmaceutical  Development & Supply and led a number of radiopharmaceutical  development programs in imaging and therapy. Prior to joining POINT,  Bill served as CFO in the Biopharmaceutical sector. Bill is also a  former senior audit partner from Ernst and Young responsible for leading  the firm’s IPO practice.

“This growth of  POINT’s executive team will continue to accelerate the development of  our radioligand platform,” added Dr. McCann. “With the recent completion  of our $20M series A financing, announcement of our 77,000 sqft  radioligand manufacturing facility in Indianapolis, and upcoming launch  of the Phase 3 clinical trial for PNT2002, our 177Lu-PSMA  radiotherapeutic for the treatment of metastatic castrate-resistant  prostate cancer, POINT has assembled all the key pieces necessary to  execute. POINT is well positioned to achieve our mission of making  radioligands applicable to more cancers, accessible to more people,  thereby improving the lives of patients and their families.”

POINT  has a strong pipeline of exciting radioligand treatments for a variety  of cancer indications. The Company will disclose more about these  programs in the coming months. POINT continues to pursue additional opportunities for pipeline expansion.